Navigation Links
US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Date:8/16/2009

EAST HANOVER, N.J., Aug. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI)(4).

The same medicinal product as Betaseron(R)*, Extavia offers patients and physicians a new branded version of interferon beta-1b, a first-line disease-modifying therapy that has been a standard-of-care for MS in the US for more than 16 years(1). Extavia will be marketed by the Pharmaceuticals Division of Novartis.

"Interferon is a mainstay of treatment in MS," said Doug Jeffery, MD, Associate Professor at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, USA. "With the approval of Extavia, patients have another option with a well-established safety and efficacy profile to help manage this disease."

MS is estimated to affect approximately 400,000 patients in the US, of whom more than 80% have relapsing-remitting MS(5). MS is one of the most common causes of neurological disability in young adults. It is a chronic autoimmune disease in which the body's immune system attacks the myelin sheath, or protective tissue surrounding the nerve fibers that carry electrical signals in the brain(6). The destruction of myelin causes problems with muscle control and strength, vision, balance, sensation and mental function(7).

"Novartis has been a leader in neuroscience for more than 50 years, having pioneered a numb
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
2. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
3. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
4. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
5. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
6. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
7. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
8. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
11. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013   Life Technologies ... a licensing agreement granting Suzhou Ribo Life Sciences ... siRNA therapeutics in China ... formulate proprietary siRNA molecules in combination with Invivofectamine® ... address human diseases with high unmet medical need ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  ... company focused on the development and commercialization of novel ... announced the pricing of an underwritten public offering of ... offering price of $33.01 per share.  In addition, Intercept ... up to an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...
(Date:6/19/2013)... Boca Raton, FL (PRWEB) June 19, 2013 ... spoke about the positive changes and growth that has occurred ... his nationwide travel club. , Shuman said, "Travel Services has ... program to heights beyond belief. Membership is up, even ... agents to meet the demands of members." , Having been ...
(Date:6/19/2013)... disease Amyotrophic lateral sclerosis (ALS), also known as Lou ... can be classified into four distinct stages, report pathologists ... of Pennsylvania in the Annals of Neurology . ... tissues shows, for the first time, how the fatal ... the central nervous system to other regions of brain ...
(Date:6/19/2013)... derived from a naturally occurring compound (apocynin), has ... with Parkinson,s Disease symptoms by preventing deficits in ... the May 28, 2013 edition of ... postdoctoral fellow at the Medical College of Wisconsin ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
Breaking Medicine News(10 mins):Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3
... one of the worlds leading causes of blindness could be ... discovery here. , In experiments with laboratory rats, scientists at ... a potential new therapy for uveitis the inflammation of ... the outer surface of the eyeball and includes the iris. ...
... ... Sept. 28 Registered nurses at up to 16,Northern California hospitals, ... strike in October that could involve up to 5,500 RNs at,facilities ... Yuba City and Marysville. Strike notices are being sent today ...
... VAWith extensively drug-resistant tuberculosis, life-threatening drug-resistant respiratory and ... headlines, infectious diseases physicians are applauding Rep. Jim ... introducing H.R. 3697, the Strategies To Address Antimicrobial ... The STAAR Act has the potential to save ...
... 28 Healthcare,Technologies Ltd. (NASDAQ: HCTL ), ... meeting of its shareholders for the approval of,the ... Bioventures,Inc. and Gamida for Life B.V., originally scheduled ... to allow shareholders additional time to fully consider,the ...
... Curtail Infant,Deaths, WASHINGTON, Sept. 28 The ... new civil rights issue" and,requires a revised set ... by the Joint Center for Political and Economic,Studies., ... to Love: Infant Mortality,Commission, which was established by ...
... program is improving air quality, agency claims , , FRIDAY, ... (NOx) from power plants, cars and other industry are ... for less ozone and therefore less smog and healthier ... NOx Budget Trading Program annual report from the U.S. ...
Cached Medicine News:Health News:New discovery may improve treatment of one of the world's leading causes of blindness 2Health News:RNs to Announce October Strike of 5,500 Nurses 2Health News:Infectious diseases experts applaud bill against 'bad bugs' 2Health News:Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction 2Health News:Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction 3Health News:Joint Center Says New Approach Required to Reduce Black Infant Mortality 2Health News:Joint Center Says New Approach Required to Reduce Black Infant Mortality 3Health News:Less Smog Now in Eastern U.S.: EPA 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... BD Beaver Clear Cornea Incision System ... specifically for the Cataract surgeon. The System ... an alternative to costly diamond knives. ... shield that is designed to both protects ...
... Carl Zeiss Meditec's technological expertise ... retinal disease became apparent with revolutionary ... system. Now, with the introduction of ... expertise is being applied to high-resolution, ...
... the eyeglasses in the EZ Meter and ... automatically display the measurement results on its ... detection to data printout makes this the ... and private offices.,In addition to being extremely ...
Medicine Products: